Universal Ibogaine — Fact Sheet (December 2023)

4 slides from Universal Ibogaine's fact sheet, December 2023

Slide 1: Company Overview
UL) (ii) 2 3 @ ® © 2 G 2 @ 4 UNIVERSAL IBOGAINE Dr. Rami Batal, PharmD/PhD Chief Executive Officer Greg Leavens, CPA Chief Financial Officer Dr. lan Rabb Chief Clinics Officer Nick Karos Director of Capital Markets Hirpal Hundial Director of Clinical Services Chief lan Campbell, MBA Chairman (Indepe
Slide 2: Share structure and ibogaine background
In # millions. Exercise Price Shares issued and outstanding at August 31, 202] (notes 1) 190.3 Options (brokers and PSQ Directors) Options (UI D & Os) $0.10 ] to 2years 5 years Performance shares - Directors and CEO (based on clinical trials and other targets) n/a n/a 37 Advisors warrants Dec 31,202
Slide 3: Why Universal Ibogaine?
Ve hy UNIVERSALIBOGAINE ? Offers an opportunity to help tackle the scourge of addiction. We present an ethical, medically supervised and regulatory- sanctioned channel to participate in the PSYCHEDELICS space Our ibogaine “biotech” play is inherently “de-risked” due to the real-world data/evidence b
Slide 4: Pre-CTA Meeting timeline
--2021-- Q4 Pre-CTA Meeting CTA Submission NOL, Ph2/HPOC Initiation* *Human proof of concept study (usually aligned with a ph28 (phase) development stage) --2022-- Q4 (Onward) Ph2/HPOC Completion Ph2/HPOC Readout Special Access (or Ph3/pivotal Start) Pre-CTAY Meeting Clinic 3+ Licensing / Franchisin